Experience

1315 Capital

• United States
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Co-Founder & Partner

  • May 2014 - Present

  Philadelphia, PA 1315 Capital provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous niche market sub-segments and business models where high-quality management teams can rapidly grow small platform companies, in a capital efficient way, into large and important… Show more 1315 Capital provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies, the latter including businesses focused on cost containment and digital health. We believe that these investment areas are attractive largely due to numerous niche market sub-segments and business models where high-quality management teams can rapidly grow small platform companies, in a capital efficient way, into large and important businesses. The firm targets $10-$40 million investments in commercial healthcare entities that have the potential to scale to approximately $50-$100 million of revenue, a highly attractive level for acquisition or to access the public markets. Show less



Palm Ventures

• Saudi Arabia
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Managing Director

  • Sep 2010 - May 2014

  Greenwich, CT Palm Ventures, LLC, founded in 1992, is an investment company focused on investing in and building businesses in partnership with management teams and a small group of substantial investors. Our primary investment focus is on companies which have a positive and transformative impact on society and generate predictable revenue streams in fragmented industries.



Galen Partners

• United States
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Principal

  • 2004 - Sep 2010

  Galen Partners is a leading healthcare private equity firm that focuses on growth equity investments in healthcare technology-enabled services, medical devices and specialty pharmaceutical companies. Galen has invested in more than 70 companies since 1990 and has nearly $1 billion under management. The firm actively participates in its investments that range from $10 million to $30 million of private equity capital.



Medtronic

• United States
• Medical Equipment Manufacturing
• 700 & Above Employee

• Business Development

  • May 2003 - Aug 2003

  Medtronic, Inc. is the world's leading medical technology company, controlling more than half of the $8 billion global heart-pacing market, which includes pacemakers and defibrillators. The company's products and services also include implantable neurological pain, tremor, spasticity, and incontinence management systems; heart valves; catheters and stents for angioplasty; implantable drug administration systems; hydrocephalic shunts; autotransfusion equipment; disposable devices for handling… Show more Medtronic, Inc. is the world's leading medical technology company, controlling more than half of the $8 billion global heart-pacing market, which includes pacemakers and defibrillators. The company's products and services also include implantable neurological pain, tremor, spasticity, and incontinence management systems; heart valves; catheters and stents for angioplasty; implantable drug administration systems; hydrocephalic shunts; autotransfusion equipment; disposable devices for handling and monitoring blood during surgery; and instruments and devices used in surgical procedures of the head and spine and by ear, nose, and throat physicians. Show less



Novoste Corporation

• Medical Equipment Manufacturing
• 1 - 100 Employee

• Business Development & Finance

  • 2000 - 2002

  Novoste Corporation is a leader in the emerging field of vascular brachytherapy for the treatment of restenosis. Brachytherapy is radiation therapy which is administered with a radioactive source placed in or near the target tissue.

• Venture Capital Associate

  • 1997 - 1999


Dillon Read & Company

• Corporate Finance Analyst

  • 1995 - 1997

  Formed 1920 from William A. Read & Company. The firm was acquired by Swiss Bank Corporation in 1997, and merged into S.G. Warburg & Co., becoming Warburg Dillon Read. The remnants are presently part of UBS.